MetaCap

Pasithea Therapeutics (KTTA) vs Psyence Biomedical (PBM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pasithea Therapeutics (KTTA) has outperformed Psyence Biomedical (PBM) over the past year, gaining 63.9% versus a loss of 94.9%. Pasithea Therapeutics is the larger company by market cap ($17.6 million vs $15.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KTTA+63.94%PBM-94.90%
+428%+154%-121%
Nov 21, 20251 yearNov 20, 2026
KTTA-98.95%PBM-100.00%
+25%-41%-106%
Dec 6, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KTTA versus PBM key metrics
MetricKTTAPBM
Share price$0.4787$2.97
Market cap$17.59M$15.80M
1-day change-0.48%+3.85%
YTD return-62.89%-89.90%
1-year return+63.94%-94.90%
5-year return-99.40%—
EPS (TTM)$-1.38$-12.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-20.43M$1.01M
52-week high$2.06$73.44
52-week low$0.32$1.92
Distance from 52-week high-76.76%-95.96%
Analyst consensusnone—
Avg. price target upside+526.70%—
Average volume705.64K61.93K
Shares outstanding36.75M5.32M
Employees512
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KTTA has outperformed PBM by 158.8 percentage points over the past year.

About Pasithea Therapeutics

KTTA stock →

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Psyence Biomedical

PBM stock →

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

KTTA vs PBM FAQ

Which is bigger, Pasithea Therapeutics or Psyence Biomedical?

Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $17.59M compared with $15.80M for Psyence Biomedical (PBM).

Which stock has performed better over the past year, KTTA or PBM?

KTTA returned +63.94% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.

Are Pasithea Therapeutics and Psyence Biomedical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons